IPP Bureau
Astellas submits new drug application for Zolbetuximab in Japan
By IPP Bureau - June 13, 2023
Ministry of Health, Labour and Welfare to evaluate zolbetuximab as treatment option for patients with advanced gastric and gastroesophageal cancers
Solvay to build a multipurpose microbiology lab in Europe
By IPP Bureau - June 13, 2023
The new lab will enable the Group to accelerate its efforts in this area, building new competencies and capabilities, as well as strengthening Solvay’s ability to develop breakthroughs in biodegradable-by-design solutions.
GSK receives USFDA file acceptance for Jemperli plus chemotherapy for the treatment of endometrial cancer
By IPP Bureau - June 12, 2023
Application being reviewed under the FDA Project Orbis framework, which enables concurrent reviews among US, Australia, Canada, Switzerland, Singapore and United Kingdom health authorities
Novartis unveils results of survey on chronic myeloid leukemia
By IPP Bureau - June 12, 2023
Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability goals across all lines of therapy
Novartis to acquire Chinook Therapeutics for US$ 3.2 bn
By IPP Bureau - June 12, 2023
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Mandaviya inaugurates CGHS Wellness Centres in Chandigarh and Panchkula
By IPP Bureau - June 12, 2023
Coverage of CGHS cities has expanded from 25 cities in 2014 to 80 in 2023
Asence Pharma commences new plant at Ranoli, Vadodara
By IPP Bureau - June 10, 2023
The new API plant is set up to meet all domestic and international regulatory standards and will manufacture niche molecules that have a global requirement
Indoco's Baddi facility receives EUGMP certification from Health Authority of Germany
By IPP Bureau - June 10, 2023
The EU certification will support supplies of drug products registered in Europe, from this manufacturing site
Zydus announces Phase IV EVIDENCES-XI trial to generate Real World Evidence of Saroglitazar Mg in NAFLD patients with comorbidities
By IPP Bureau - June 10, 2023
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
Univar Solutions expands specialty pharmaceutical and nutraceutical ingredient portfolios with Grace Syloid FP Silica
By IPP Bureau - June 09, 2023
Agreement provides customers in the majority of Europe* access to supply through Univar Solutions distribution network
Cosette Pharmaceuticals acquires Intrarosa from Endoceutics
By IPP Bureau - June 09, 2023
Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
Lantern Pharma leverages AI platform to develop breakthrough ADCs with Bielefeld University
By IPP Bureau - June 09, 2023
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Health Ministry organizes webinar on Non-Alcoholic Fatty Liver Diseases
By IPP Bureau - June 09, 2023
Health Secretary highlights the need for capacity building programmes for Medical Officers to tackle Non Communicable Diseases at the primary level
Zydus receives final approval from USFDA for Esomeprazole Magnesium
By IPP Bureau - June 09, 2023
Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 mg and 40 mg had annual sales of USD 42 mn in the United States (IQVIA MAT April 2023)
